scispace - formally typeset
D

Dilhan Weeraratne

Researcher at IBM

Publications -  16
Citations -  425

Dilhan Weeraratne is an academic researcher from IBM. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 5, co-authored 12 publications receiving 169 citations.

Papers
More filters
Journal ArticleDOI

Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.

TL;DR: Using the epitope information along with variants of the virus, it is found several variants which might cause drifts, including 23403A>G variant in spike protein B-cell epitope, which is observed frequently in European countries, such as the Netherlands, Switzerland, and France, but seldom observed in China.
Journal ArticleDOI

Precision Medicine, AI, and the Future of Personalized Health Care

TL;DR: Translational research exploring the convergence of artificial intelligence and precision medicine will help solve the most difficult challenges facing precision medicine, especially those in which nongenomic and genomic determinants, combined with information from patient symptoms, clinical history, and lifestyles, will facilitate personalized diagnosis and prognostication.
Posted ContentDOI

Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment

TL;DR: Using the epitope information along with variants of the virus, it is found several variants which might cause drifts, including 23403A>G variant in spike protein B-cell epitope, which is observed frequently in European countries, such as the Netherlands, Switzerland, and France, but seldom observed in China.
Posted ContentDOI

Introductions and evolutions of SARS-CoV-2 strains in Japan

TL;DR: In this paper, the authors analyzed 30493 genomes sampled in Japan were analyzed to understand the strains, heterogeneity and temporal evolution of different SARS-CoV-2 strains and identified 12 discrete strains with a substantial number of cases with most strains possessing the spike (S) D614G and nucleocapsid (N) 203_204delinsKR mutations.
Journal ArticleDOI

A Narrative Review of Emerging Therapeutics for COVID-19.

TL;DR: This review provides frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging candidate therapeutics for COVID-19 and two main categories of pharmaceutical therapeutics are showing promise—those with antiviral activity directly addressing infection and those that counteract the inflammatory cytokine storm induced by severe disease.